Our California stem cell agency, CIRM, started as a baby even before I came to California in 2006 to start my lab here at UC Davis School of Medicine, but now CIRM or to use its full name the California Institute for Regenerative Medicine is I’d say a full-grown, mature adult at about age 13 […]
Poll on refunding CIRM on eve of informational legislative hearing Read More »
There’s some recent stem cell good news out there including new papers and biotech developments. The stem cell and regenerative medicine field is really diverse and runs the gamut from really worrying stuff to very exciting, legit developments. In this post, I’m going to focus on the encouraging recent developments. What do I see as
Stem cell good news on biotechs & cool new organoid paper Read More »
Are you a risk-taker or do you do everything possible to avoid risks? Taking risks in science is necessary, but is there a wise way to take the risks you do? Science and medicine need a certain amount of risk and risk-takers to make transformative leaps forward. The risks in biomedical science can be conceptual
Some thoughts on taking risks in science & medicine Read More »
Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. As of December 12, 2023 there are 85 RMATs in the public domain. I also include FDA data on RMAT submissions via an FDA RMAT resource
Updated FDA granted RMAT List (85) Read More »
When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is a new interview with the company’s CEO Paul Laikind. For past posts on ViaCyte see here, which
ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech Read More »
A list of stuff for your weekend reading enjoyment ranging from research pubs to news to commentary. Electrical Stimulation Steers Neural Stem Cells. Way to go UC Davis team; see image at right. Stem cell therapies: medical experts call for strict international rules. A team calls for global efforts. Stem cells in court: historical trends in US
TGIF: Stem cell and science weekend reads Read More »
By Jeanne Loring “Mutation” and “cancer” are eye-catching words for a headline; add “stem cells” and there is a good chance that a lot of people will hear about it. These words have been liberally used in the press to describe the results of a recent publication: “Human pluripotent stem cells recurrently acquire and expand
Mutations in pluripotent stem cells: No, the sky is not falling Read More »
By Amritha Jaishankar Happy Maryland Day from the Maryland Stem Cell Research Fund (MSCRF) at Maryland Technology Development Corp. (TEDCO)! This year, here at MSCRF, we are skipping the crabs, old bay and beer and choosing instead to spend the weekend engaged in scientific review! As we commemorate the day the first settlers stepped on to
Guest Post from the Maryland Stem Cell Research Fund Read More »
Happy St. Patrick’s Day from the Irish Stem Cell Foundation (www.stemcell.ie)! I’ve included a few picture from the parade here in Ireland. Scientifically, Ireland is going through a lean period. The national science funding agency SFI is having its first grant call in 2 years. If recent history is a predictor, they are more likely
On St. Patrick’s Day, an update on stem cells in Ireland by Stephen Sullivan Read More »
San Diego-based stem cell business Stemgenex is the subject of a suit over allegations about stem cell treatments. The company has now filed a motion to dismiss the case. To me as a non-attorney, the Stemgenex motion to dismiss seems to emphasize overall vagueness of the plaintiff’s case and argues in part that there is insufficient detailed support of each claim. From
Stemgenex motion to dismiss aims to rebut stem cell suit claims Read More »